A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
A phase 2 trial of TQB2102 in non-small-cell lung cancer and small-cell lung cancer, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.
Overview
A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality is a phase 2 interventional study registered as NCT06496490 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with 270 participants planned, started 2024-08-06 and due to reach its primary completion in 2026-06. Interventions recorded: TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
- TrialThe Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
- TrialA Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
- TrialA Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
- TrialA Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
- TrialClinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
- TrialA Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
- TrialClinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors